US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Biomarkers Market Research Reports & Industry Analysis

The high specificity required of biomarkers in research, drug development and clinical diagnostics creates significant diversity in the global biomarkers market. The greatest focus in biomarkers development is oncology with cancer biomarkers occupying the largest space at over 25% of the market. Biomarkers are parameters or analytes integral to or associated with a biochemical, anatomical, pathogenic, pharmacologic or molecular (genetic) process of clinical interest.

Biomarker discovery continues to power the development of in vitro diagnostic (IVD) tests used to diagnose disease and health conditions, predict patient response to therapy, and monitor therapeutic effects and patient health. Ideal biomarkers have excellent sensitivity and specificity in terms of identifying disease, determining disease state, or evaluating patient response to therapy. Biomarkers are generally proteins (products of gene expression) or nucleic acid sequences (either RNA or DNA); small molecules that are products of metabolism may also serve as biomarkers.

The proliferation of biomarkers is a result of greater clinical understanding of the interconnections between genetics, proteomics and gene expression, disease susceptibility, disease manifestation, and disease susceptibility to select therapies. Biomarkers can be classified as natural history markers (allow for the detection and isolation of a particular cell type), drug activity markers (indicate patient response to pharmological intervention), or surrogate markers (markers that can be used as an alternative to traditional endpoints such as morbidity and mortality to evaluate the effectiveness of a therapy in treating disease). Genomic research is expected to further expand the availability of biomarkers for various diseases and make significant contributions to personalized medicine.

In addition to cancer biomarkers, biomarkers are also available for cardiac function and episodes, other cardiovascular conditions, coagulation or hemostasis, endocrine function, blood sugar management, autoimmune disorders, inflammation, specific infectious diseases, sepsis, and neurological disorders. Over half of the biomarkers market exists in clinical applications, the rest in drug development, research and clinical trial applications. Biomarkers are broadly used for disease risk assessment, diagnosis, screening, treatment or therapy selection, and therapeutic monitoring.

RSS Feeds

Biomarkers Industry Research & Market Reports

< prev 1    3  4  5  6  7  
Future Horizons and Growth Strategies in the German Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next ten years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the Spanish Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the German Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 3,850
Future Horizons and Growth Strategies in the Japanese Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 4,850
MicroRNAs in Cancer Drug Pipeline Update 2015
6/17/2015 | published by: BioSeeker Group AB
... with minimal toxicities either as a monotherapy or perhaps even more likely in a combinatorial drug setting. miRNA may also hold great potential as biomarkers, albeit a lot of work is a head of us ...  |  read more...
USD 6,750
2015 Immunodiagnostics: Spot Fast-Growing Market Segments - Therapeutic Drug Monitoring (TDM), Endocrine Function, Tumor Markers, Special Chemistry, Immunoproteins, Drugs of Abuse
6/8/2015 | published by: VPGMarketResearch.com
... and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The report ...  |  read more...
USD 24,500
Future Horizons and Growth Strategies in the Global Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... markers - Analyzes applications of emerging diagnostic technologies - Forecasts sales of major tumor markers by country and market segment - Profiles leading market players and potential entrants - Suggests alternative business expansion strategies for ...  |  read more...
USD 34,750
Future Horizons and Growth Strategies in the European Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... cancer diagnostics market during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor ...  |  read more...
USD 19,700
Future Horizons and Growth Strategies in the French Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the Italian Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the Japanese Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 7,600
Future Horizons and Growth Strategies in the UK Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
Future Horizons and Growth Strategies in the US Tumor Marker Testing Market 20154: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 9,800
Future Horizons and Growth Strategies in the French Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 3,850
Future Horizons and Growth Strategies in the Italian Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 3,850
Future Horizons and Growth Strategies in the Spanish Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 3,850
Future Horizons and Growth Strategies in the UK Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, ...  |  read more...
USD 3,850
Future Horizons and Growth Strategies in the US Hospital Tumor Marker Testing Market 2015: Supplier Shares and Country Forecasts
6/16/2015 | published by: VPGMarketResearch.com
... economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, ...  |  read more...
USD 6,500
Emerging Diagnostic Imaging Market – Devices (Nuclear Imaging Systems, 3D imaging, Tactile imaging, Tomography, Emerging Diagnostic Biomarkers, Wearable diagnostic devices), Global Industry Analysis, Growth, Trends, Forecast 2014-2020
5/22/2015 | published by: Occams Business Research & Consultancy
... a patient’s physical condition, which is then used to diagnose, monitor or treat medical conditions, thus playing an important role in improving public health of all age groups. X-ray based examinations are crucial in all ...  |  read more...
USD 4,000
2015 Strategies in the Spanish Tumor Marker Testing Market
5/15/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
2015 Strategies in the UK Tumor Marker Testing Market
5/15/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
2015 Strategies in the French Tumor Marker Testing Market
5/15/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
2015 Strategies in the German Tumor Marker Testing Market
5/15/2015 | published by: VPGMarketResearch.com
... during the next ten years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
2015 Strategies in the Italian Tumor Marker Testing Market
5/15/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 6,800
2015 Strategies in the Japanese Tumor Marker Testing Market
5/15/2015 | published by: VPGMarketResearch.com
... during the next five years. Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ...  |  read more...
USD 7,600
< prev 1    3  4  5  6  7